NORTH AMERICA AND EUROPE AGE-RELATED MACULAR DEGENERATION THERAPEUTICS MARKET ANALYSIS

Regional Analysis

North America & Europe Age-Related Macular Degeneration Therapeutics Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the North America & Europe age-related macular degeneration therapeutics market over the forecast period, owing to increasing launches of products. For instance, on April 7, 2021, LumiThera, Inc., a U.S.-based commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration (AMD) patients. The prospective, double-masked, randomized, multi-center, clinical trial, titled LIGHTSITE II, was conducted in eight leading retinal centers based in the U.K., Germany, Spain, Italy, and France. The objective was to treat dry AMD subjects over the course of three rounds of PBM sessions every four months with a duration of 10 months. Results showed a steady improvement over time in BCVA measurements from baseline with the shortened PBM treatment intervals. Previously, LIGHTSITE I study results demonstrated some remission of visual benefits between PBM treatments delivered every six months.  The benefits of four-month treatment intervals were more consistent in maintaining vision outcomes.

North America & Europe Age-Related Macular Degeneration Therapeutics Market Report Coverage:

• North America: U.S. and Canada
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe